Cagrilintide
$Late-stage pharmaceutical obesity program
Cagrilintide is an amylin analog. In the CagriSema combination, it is paired with semaglutide so that one component strengthens satiety/satiation signaling while the GLP-1 component reduces appetite and improves glycemic control.
This one has substantially stronger evidence than most research peptides because it is supported by large Phase 3 obesity trials. The important distinction is that CagriSema is not simply “stronger semaglutide.” It is a two-pathway fixed-dose product with its own tolerability and titration profile.
Compare CagriSema with tirzepatide and retatrutide using trial population, estimand, adherence, dose escalation, and adverse-event discontinuation, not just headline percent weight loss.
Classification details
- Cagrilintide is a long-acting synthetic amylin analog developed by Novo Nordisk.
- In CagriSema, cagrilintide is paired with semaglutide as an investigational fixed-dose obesity product.
- Cagrilintide is a long-acting amylin analog, not a GLP-1 agonist. This distinction matters because it complements incretin drugs through satiety/amylin biology rather than duplicating GLP-1 signaling.
- Cagrilintide targets amylin and calcitonin-receptor pathways involved in satiety, meal termination, gastric emptying, and glucagon regulation.
- These pathways complement GLP-1 signaling rather than replacing it.
- The combination is intended to increase both appetite suppression and earlier meal satisfaction.
- The practical mechanism is appetite and weight regulation through amylin-receptor pathways, especially satiety and meal-size effects. It is not a glucose-control drug in the same way as GLP-1/GIP agonists.